title: Islet autotransplantation for the prevention of surgical diabetes after extended pancreatectomy for the resection of benign tumors of the pancreas.
abstract: OBJECTIVE
  The objective of this article is to report a single-center experience with islet autotransplantation after extensive pancreatic resection for benign tumors of the pancreas.
  
  
  METHODS
  Seven patients underwent extensive left pancreatectomy for benign lesions located at the neck of the pancreas. Once an unequivocal diagnosis of a benign nature was ascertained, the rest of the specimen was processed and the unpurified pancreatic digest was infused into the portal vein. The results were compared with those of 8 autotransplantations performed for chronic pancreatitis over the same period.
  
  
  RESULTS
  Tumors were 4 cystadenomas, 2 insulinomas and 1 neuroendocrine tumor. Mean islet yields were 275,000 islet equivalents (IEQ) versus 129,000 in chronic pancreatitis (P =.04) or 6700 IEQ/g of tissue versus 1900 (P =.002), resulting in transplantation of 4200 IEQ/kg body weight vs 2150 in chronic pancreatitis (P =.03), respectively at 4-month to 7.5-year follow-up, all patients are alive and 6 of 7 are off insulin. All patients off insulin after at least 1 year currently have a normal IVGTT, with K values ranging between -1.19 and -2.36 (normal < -1.00). All patients, including 1 on insulin, display positive basal and glucagon-stimulated C-peptide levels.
  
  
  CONCLUSIONS
  Compared with chronic pancreatitis tissue resected for benign tumors is more likely to achieve good islet yields, and thus insulin independence after autotransplantation. Islet autotransplantation should be considered when extensive pancreatectomy is required for resection of a benign tumor, and only if the benign nature of the lesion is demonstrated unequivocally.
authors.affiliation: Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland. thierry.berney@hcuge.ch
authors.forename: T
authors.initials: T
authors.lastname: Berney
authors.forename: Z
authors.initials: Z
authors.lastname: Mathe
authors.forename: P
authors.initials: P
authors.lastname: Bucher
authors.forename: S
authors.initials: S
authors.lastname: Demuylder-Mischler
authors.forename: A
authors.initials: A
authors.lastname: Andres
authors.forename: D
authors.initials: D
authors.lastname: Bosco
authors.forename: J
authors.initials: J
authors.lastname: Oberholzer
authors.forename: P
authors.initials: P
authors.lastname: Majno
authors.forename: J
authors.initials: J
authors.lastname: Philippe
authors.forename: L
authors.initials: L
authors.lastname: Bühler
authors.forename: P
authors.initials: P
authors.lastname: Morel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002096:C-Peptide / Q000097:blood; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy / Q000009:adverse effects*; D010190:Pancreatic Neoplasms / Q000601:surgery*; D010195:Pancreatitis / Q000601:surgery; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D002096:C-Peptide